Publisher
Springer Science and Business Media LLC
Reference201 articles.
1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
2. Beaver, J. A. et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer Res. 21, 4760–4766 (2015).
3. Shah, A. et al. FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin. Cancer Res. 24, 2999–3004 (2018).
4. US Food and Drug Administration. FDA approves abemaciclib for HR-positive, HER2-negative breast cancer. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer (2017).
5. US Food and Drug Administration. FDA approves abemaciclib with endocrine therapy for early breast cancer. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-endocrine-therapy-early-breast-cancer (2021).